Former Advisory Panel Member
Jasvinder Singh, MD, MPH
Represented: ResearchersTerm Ended August 2024
Conflicts of Interest:
As of September 1, 2021:
- Crealta/Horizon, Consultant
- TPT Global Tech, Stock
- Simply Speaking, Speaker
- Medisys, Consultant
- Fidia, Consultant
- PK Med, Consultant
- Two Labs, Inc., Consultant
- Adept Field Solutions, Consultant
- Clinical Care Options, Consultant
- Clearview Health Partners, Consultant
- Putnam Associates, Consultant
- Focus Forward, Consultant
- Navigant Consulting, Consultant
- Spherix, Consultant
- MedIQ, Consultant
- Jupiter Life Science, Consultant
- UBM LLC, Consultant
- Trio Health, Consultant
- Medscape, Consultant
- WebMD, Consultant
- Practice Point Communications, Consultant
- National Institutes of Health, Consultant
- American College of Rheumatology, Consultant
- Vaxart Pharmaceuticals, Stock
- Atyu Biopharma, Stock
- Charlotte’s Web Holdings, Stock
- Outcomes Measures in Rheumatology, Executive
- University of Alabama at Birmingham (UAB) Cochrane Musculoskeletal Group Satellite Center on Network Meta-analysis, Employer
- FDA Arthritis Advisory Committee, Board Member
- Veterans Affairs Rheumatology Field Advisory Committee, Board Member
Singh served on the Advisory Panel on Rare Disease from August 2021 - August 2024.